Barclays analyst Peter Lawson lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $5 and keeps an Overweight rating on the shares. The company reported a significant fiscal 2025 guidance negative reset along with a Q1 miss, which will pressure the stock near term, but new the new guidance “looks more reasonable,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics’ Earnings Call: Mixed Sentiments and Future Prospects
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- Iovance Biotherapeutics price target lowered to $5 from $10 at TD Cowen
- Iovance Biotherapeutics price target lowered to $25 from $30 at Chardan
- Iovance price target lowered to $20 from $32 at H.C. Wainwright